SLDB News & Events

Solid Biosciences announced that the first participant has been dosed in IMPACT DUCHENNE, the company's multi-country, placebo-controlled, randomized, double-blind, Phase 3 clinical trial investigating SGT-003 for the treatment of Duchenne muscular dystrophy.

Solid Biosciences announced that the European Commission, acting upon the positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products, has granted orphan drug designation to SGT-003 for the treatment of Duchenne muscular dystrophy.